Pancreatic Adenocarcinoma Pathology: Changing "landscape"

Overview

Journal J Gastrointest Oncol

Date 2015 Aug 12

PMID 26261723

Citations 38

Authors

Lodewijk A A Brosens

Wenzel M Hackeng

G Johan Offerhaus

Ralph H Hruban

Laura D Wood

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is a devastating disease. At time of diagnosis the disease is usually advanced and only a minority of patients are eligible for surgical resection. The overall 5-year survival is 6%. However, survival of patients with early stage pancreatic cancer is significantly better. To improve the prognosis of patients with pancreatic cancer, it is essential to diagnose and treat pancreatic cancer in the earliest stage. Prevention of pancreatic cancer by treating noninvasive precursor lesions just before they invade tissues can potentially lead to even better outcomes. Pancreatic carcinogenesis results from a stepwise progression in which accumulating genetic alterations drive neoplastic progression in well-defined precursor lesions, ultimately giving rise to an invasive adenocarcinoma. A thorough understanding of the genetic changes that drive pancreatic carcinogenesis can lead to identification of biomarkers for early detection and targets for therapy. Recent next-generation sequencing (NGS) studies have shed new light on our understanding of the natural history of pancreatic cancer and the precursor lesions that give rise to these cancers. Importantly, there is a significant window of opportunity for early detection and treatment between the first genetic alteration in a cell in the pancreas and development of full-blown pancreatic cancer. The current views on the pathology and genetics of pancreatic carcinogenesis that evolved from studies of pancreatic cancer and its precursor lesions are discussed in this review.

Citing Articles

Spatial transcriptomic analysis drives PET imaging of tight junction protein expression in pancreatic cancer theranostics.

Wang J, Seo J, Kare A, Schneider M, Pandrala M, Tumbale S Nat Commun. 2024; 15(1):10751.

PMID: 39737976 PMC: 11686138. DOI: 10.1038/s41467-024-54761-6.

The Impact of a Ketogenic Diet on Late-Stage Pancreatic Carcinogenesis in Mice: Efficacy and Safety Studies.

Cortez N, Bacha T, Ead A, Rodriguez Lanzi C, Lacroix C, Franceschetti A Nutrients. 2024; 16(22).

PMID: 39599705 PMC: 11597385. DOI: 10.3390/nu16223919.

Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application.

Archasappawat S, Al-Musawi F, Liu P, Lee E, Hwang C Biomolecules. 2024; 14(11).

PMID: 39595558 PMC: 11592027. DOI: 10.3390/biom14111381.

Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.

Weitz J, Nishizaki D, Liau J, Patel J, Ng I, Sun S J Clin Oncol. 2024; 43(6):705-715.

PMID: 39413348 PMC: 11829827. DOI: 10.1200/JCO.24.00511.

The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.

Mottini C, Auciello F, Manni I, Pilarsky C, Caputo D, Caracciolo G J Exp Clin Cancer Res. 2024; 43(1):198.

PMID: 39020414 PMC: 11256648. DOI: 10.1186/s13046-024-03117-5.

References

Hruban R, Takaori K, Canto M, Fishman E, Campbell K, Brune K . Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg. 2007; 14(3):255-63. DOI: 10.1007/s00534-006-1170-9. View

Schutte M, Hruban R, Geradts J, Maynard R, Hilgers W, Rabindran S . Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997; 57(15):3126-30. View

Sadakari Y, Kanda M, Maitani K, Borges M, Canto M, Goggins M . Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. Clin Transl Gastroenterol. 2014; 5:e62. PMC: 5543403. DOI: 10.1038/ctg.2014.14. View

Kim S, Wu T, Lee J, Yun Y, Issa J, Hamilton S . Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod Pathol. 2003; 16(11):1086-94. DOI: 10.1097/01.MP.0000094088.37888.A6. View

Sato N, Ueki T, Fukushima N, Iacobuzio-Donahue C, Yeo C, Cameron J . Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 2002; 123(1):365-72. DOI: 10.1053/gast.2002.34160. View

Wu J, Matthaei H, Maitra A, Dal Molin M, Wood L, Eshleman J . Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011; 3(92):92ra66. PMC: 3160649. DOI: 10.1126/scitranslmed.3002543. View

Furukawa T, Kloppel G, Adsay N, Albores-Saavedra J, Fukushima N, Horii A . Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005; 447(5):794-9. DOI: 10.1007/s00428-005-0039-7. View

Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond V . Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009; 302(16):1790-5. PMC: 4091624. DOI: 10.1001/jama.2009.1529. View

Hruban R, Takaori K, Klimstra D, Adsay N, Albores-Saavedra J, Biankin A . An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004; 28(8):977-87. DOI: 10.1097/01.pas.0000126675.59108.80. View

10.

Wall I, Schmidt-Wolf I . Effect of Wnt inhibitors in pancreatic cancer. Anticancer Res. 2014; 34(10):5375-80. View

11.

Crippa S, Salvia R, Warshaw A, Dominguez I, Bassi C, Falconi M . Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg. 2008; 247(4):571-9. PMC: 3806104. DOI: 10.1097/SLA.0b013e31811f4449. View

12.

Gironella M, Seux M, Xie M, Cano C, Tomasini R, Gommeaux J . Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007; 104(41):16170-5. PMC: 2042180. DOI: 10.1073/pnas.0703942104. View

13.

Fukushima N, Sato N, Prasad N, Leach S, Hruban R, Goggins M . Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene. 2004; 23(56):9042-51. DOI: 10.1038/sj.onc.1208117. View

14.

Baas I, Hruban R, Offerhaus G . Clinical applications of detecting dysfunctional p53 tumor suppressor protein. Histol Histopathol. 1999; 14(1):279-84. DOI: 10.14670/HH-14.279. View

15.

Wilentz R, Albores-Saavedra J, Zahurak M, Talamini M, Yeo C, Cameron J . Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 1999; 23(11):1320-7. DOI: 10.1097/00000478-199911000-00002. View

16.

Erdogan D, Kloek J, Lamers W, Offerhaus G, Busch O, Gouma D . Mucinous cystadenomas in liver: management and origin. Dig Surg. 2010; 27(1):19-23. DOI: 10.1159/000268110. View

17.

Matthaei H, Schulick R, Hruban R, Maitra A . Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2011; 8(3):141-50. PMC: 3236705. DOI: 10.1038/nrgastro.2011.2. View

18.

Shi C, Klein A, Goggins M, Maitra A, Canto M, Ali S . Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res. 2009; 15(24):7737-7743. PMC: 2795080. DOI: 10.1158/1078-0432.CCR-09-0004. View

19.

Schnelldorfer T, Sarr M, Nagorney D, Zhang L, Smyrk T, Qin R . Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008; 143(7):639-46. DOI: 10.1001/archsurg.143.7.639. View

20.

Iacobuzio-Donahue C, Klimstra D, Adsay N, Wilentz R, Argani P, Sohn T . Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol. 2000; 157(3):755-61. PMC: 1885701. DOI: 10.1016/S0002-9440(10)64589-0. View